IMPACT Therapeutics Inc is a China-based company mainly engaged in biotechnology research and commercialization. The Company is in the commercialization stage. The Company is committed to advancing synthetic lethality (SL)-based precision anti-cancer therapies globally. The Company's independently developed core product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC). The Company is currently developing product pipeline packages such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2.

© Copyright 1996-2026 irasia.com Ltd. All rights reserved.

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website. TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website.